08:46 AM EDT, 10/15/2025 (MT Newswires) -- Stereotaxis ( STXS ) said Wednesday it has received CE Mark approval in Europe and filed an application to the US Food and Drug Administration for its Synchrony system.

The Synchrony system is a digital platform designed to modernize interventional catheterization laboratory procedures with improved workflow and visualization, the company said.

Shares of Stereotaxis ( STXS ) were up 3.3% in recent Wednesday premarket activity.